Science Explorer Back to mapMap
Discussion
Company · Nuremberg · Germany

Crolll (Germany)

crolllgmbh.de/index.phpROR OpenAlex
Research works
1
fractional, all time
Citations
3
2.3 per fractional work
Top-10% rate
9.2%
all institutions 10.0%
Open access
25%
world 40%
International
12%
world 18%
Crolll (Germany)

Not ranked overall: Crolll (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Crolll (Germany) work in?

In all years, 46% of research at Crolll (Germany) is in Health Sciences, 23% in Physical Sciences. Its largest fields are Medicine (46%), Engineering (23%), Social Sciences (15%).

Health Sciences: 1 fractional works · 46.2% of its workMedicine: 1 fractional works · 46.2% of its workPhysical Sciences: 0 fractional works · 23.1% of its workEngineering: 0 fractional works · 23.1% of its workLife Sciences: 0 fractional works · 15.4% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 7.7% of its workImmunology and Microbiology: 0 fractional works · 7.7% of its workSocial Sciences: 0 fractional works · 15.4% of its workSocial Sciences: 0 fractional works · 15.4% of its workALL ITS WORKCrolll (Germany)1fractional works, all years
Life Sciences15%Physical Sciences23%Health Sciences46%Social Sciences15%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 5 fields, with their numbers
    1. Medicine146.2%
    1. Engineering023.1%
    1. Biochemistry, Genetics and Molecular Biology07.7%
    2. Immunology and Microbiology07.7%
    1. Social Sciences015.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 0.96× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 4.01× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 5.20× its world share, 0 worksPharmacology, Toxico…Engineering: 1.71× its world share, 0 worksEngineeringMedicine: 2.51× its world share, 1 worksMedicineEconomics, Econometrics and Finance: 1.09× its world share, 0 worksEconomics, Econometr…Social Sciences: 1.01× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 5.2×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics5.20×0 works
  2. Immunology and Microbiology4.01×0 works
  3. Medicine2.51×1 works
  4. Engineering1.71×0 works
  5. Economics, Econometrics and Finance1.09×0 works
  6. Social Sciences1.01×0 works
  7. Biochemistry, Genetics and Molecular Biology0.96×0 works

What are the most cited papers from Crolll (Germany)?

The most cited paper from Crolll (Germany) is "Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial" (Matthias P A Ebert et al., 2022), with 31 citations. Next come "An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial" (5) and "Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study" (4).

Most cited papers
#PaperReleasedCitations
1 Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial Matthias P A Ebert et al. · The Lancet Healthy Longevity Open access Jun 2022 31
2 An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial Anton Lahusen, Manfred Paul Lutz, Rui Fang et al. · Molecular Cancer Open access 22 Jul 2025 5
3 Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study Moying Li, Nadja M. Meindl‐Beinker, Martin Maenz et al. · Journal of Geriatric Oncology Open access 2 Aug 2024 4
4 1624P Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216) Manfred Paul Lutz, Nikolaus Ansorge, Gleb Barmashenko et al. · Annals of Oncology Open access Oct 2023 1
5 Nivolumab plus Ipilimumab in der Zweitlinientherapie bei älteren Patienten mit Plattenepithelkarzinom des Ösophagus: Ergebnisse einer multizentrischen Phase II Studie Matthias P A Ebert et al. · Zeitschrift für Gastroenterologie Aug 2022 0
All 8 most cited papers, with filters and sorting

Which research topics does Crolll (Germany) publish most on?

By volume in 2022-now: Millimeter-Wave Propagation and Modeling, Indoor and Outdoor Localization Technologies, Human Mobility and Location-Based Analysis and Esophageal Cancer Research and Treatment.

Millimeter-Wave Propagation and Modeling: 0 fractional worksIndoor and Outdoor Localization Technologies: 0 fractional worksHuman Mobility and Location-Based Analysis: 0 fractional worksEsophageal Cancer Research and Treatment: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksImmunotherapy and Immune…0Immunotherapy and Immune Responses: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksPancreatic and Hepatic Oncology Research: 0 fractional works
Electrical and Electronic EngineeringTransportationSurgeryOncology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Millimeter-Wave Propagation and Modeling Electrical and Electronic Engineering 0 works
  2. 2 Indoor and Outdoor Localization Technologies Electrical and Electronic Engineering 0 works
  3. 3 Human Mobility and Location-Based Analysis Transportation 0 works
  4. 4 Esophageal Cancer Research and Treatment Surgery 0 works
  5. 5 Cancer Immunotherapy and Biomarkers Oncology 0 works
  6. 6 Immunotherapy and Immune Responses Immunology 0 works
  7. 7 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  8. 8 Pancreatic and Hepatic Oncology Research Oncology 0 works
  9. 9 Colorectal and Anal Carcinomas Surgery 0 works
  10. 10 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available24.7%not open75.3%

World: 40% of research is openly available.

with international co-authors12.1%domestic only87.9%

World: 18% is written across borders.

How has Crolll (Germany)'s research output changed?

still counting2025

Other research institutions in Nuremberg

All research institutions in Nuremberg

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Crolll (Germany). Posts are plain text and can be reported.